Home › Funds › FULTON BREAKEFIELD BROENNIMAN LLC › ABBV

FULTON BREAKEFIELD BROENNIMAN LLC position in ABBV

ABBVIE INC · Health Care

FULTON BREAKEFIELD BROENNIMAN LLC reported holding 61,075 shares of ABBV (ABBVIE INC) in its Q3 2026 13F filing — a position valued at US$16.0M, representing 0.93% of its reported portfolio and ranking #23 among its reported holdings. FULTON BREAKEFIELD BROENNIMAN LLC has disclosed ABBV holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)61.08K sh
Reported value held$15.98M
Portfolio Weight0.93%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How FULTON BREAKEFIELD BROENNIMAN LLC's ABBV position evolved

FULTON BREAKEFIELD BROENNIMAN LLC first disclosed a stake in ABBV in Q3 2023 at 97,544 shares (US$14.5M). The position peaked in Q3 2025 at 86,399 shares, worth US$20.0M. Across 13 filings, FULTON BREAKEFIELD BROENNIMAN LLC increased the stake 0 time(s), trimmed it 11 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 61,075 shares valued at US$16.0M — a reduction of -653 shares quarter over quarter.. Notable position changes include a 26% trim in Q2 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 97.54K $14.54M New
Q4 2023 97.00K $15.03M Reduce
Q1 2024 95.75K $17.44M Reduce
Q2 2024 94.49K $16.21M Reduce
Q3 2024 90.76K $17.92M Reduce
Q4 2024 89.71K $15.94M Reduce
Q1 2025 86.66K $18.16M Reduce
Q2 2025 86.95K $16.14M Hold
Q3 2025 86.40K $20.00M Reduce
Q4 2025 84.70K $19.35M Reduce
Q1 2026 83.03K $18.06M Reduce
Q2 2026 61.73K $15.53M Reduce
Q3 2026 61.08K $15.98M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABBV and 13F data

ABBV (ABBVIE INC) is a Health Care company. 31 other funds we track also report a position in ABBV — the largest reported positions include Vanguard Group (US$41.31B), BlackRock Inc (US$37.62B), VANGUARD CAPITAL MANAGEMENT LLC (US$30.26B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABBV

All ABBV fund holders →

FAQ

How long has FULTON BREAKEFIELD BROENNIMAN LLC held ABBV?

FULTON BREAKEFIELD BROENNIMAN LLC has disclosed ABBV holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is FULTON BREAKEFIELD BROENNIMAN LLC's current position in ABBV?

As of Q3 2026, FULTON BREAKEFIELD BROENNIMAN LLC holds 61.08K shares of ABBV (ABBVIE INC), valued at $15.98M, representing 0.93% of its reported portfolio and ranking #23.

Has FULTON BREAKEFIELD BROENNIMAN LLC been buying or selling ABBV?

In the latest 13F filing (Q3 2026), FULTON BREAKEFIELD BROENNIMAN LLC reduced its position in ABBV. The position peaked in Q3 2025 at 86.40K shares.

Which other funds hold ABBV?

Other major institutional holders of ABBV include Vanguard Group, BlackRock Inc, VANGUARD CAPITAL MANAGEMENT LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.